New England Biolabs Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:New England Biolabs Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014177
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
New England Biolabs Inc (NEB) is a life science company that develops recombinant and native enzymes for genomic research. The company offers products such as competent cells, DNA plasmids, protein tools, buffers and strains, and others. It has applications in cloning and synthetic biology, RNA analysis, DNA amplification and PCR, DNA modification, library preparation for next generation sequencing and epigenetic, among others. It also provides interactive tools for research and experimental designs. The company has its presence with subsidiaries in Canada, China, France, Germany, Japan, Singapore and the UK. It offers its products globally through a channel of network distributors. NEB is headquartered in Ipswich, Massachusetts, the US.

New England Biolabs Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
New England Biolabs Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
New England Biolabs Inc, Medical Devices Deals, 2011 to YTD 2017 8
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
New England Biolabs Enters into Co-Development Agreement with Directed Genomics 10
Beckman Coulter Partners with New England Biolabs 11
SwitchGear Genomics Enters Into Co-Development Agreement With New England Biolabs 12
New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics 13
New England Biolabs Enters Into Co-Marketing Agreement With Imperial Life Sciences 14
Licensing Agreements 15
New England Biolabs Enters Into Licensing Agreement With Synthetic Genomics 15
SomaLogic Enters Into Licensing Agreement With New England Biolabs 16
New England Biolabs Enters Into Licensing Agreement With Sequenom 17
New England Biolabs Inc – Key Competitors 18
New England Biolabs Inc – Key Employees 19
New England Biolabs Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 22
Product News 22
Nov 07, 2017: New England Biolabs Launches NEBNext Ultra II FS Kit for Robust Enzyme-based DNA Fragmentation and Library Preparation with as Little as 100 pg of Input DNA 22
Jan 12, 2016: New England Biolabs Launches Environmentally-Friendly Monarch Kits for High-Quality DNA Purification 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
New England Biolabs Inc, Pharmaceuticals & Healthcare, Key Facts 2
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
New England Biolabs Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
New England Biolabs Inc, Medical Devices Deals, 2011 to YTD 2017 8
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
New England Biolabs Enters into Co-Development Agreement with Directed Genomics 10
Beckman Coulter Partners with New England Biolabs 11
SwitchGear Genomics Enters Into Co-Development Agreement With New England Biolabs 12
New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics 13
New England Biolabs Enters Into Co-Marketing Agreement With Imperial Life Sciences 14
New England Biolabs Enters Into Licensing Agreement With Synthetic Genomics 15
SomaLogic Enters Into Licensing Agreement With New England Biolabs 16
New England Biolabs Enters Into Licensing Agreement With Sequenom 17
New England Biolabs Inc, Key Competitors 18
New England Biolabs Inc, Key Employees 19
New England Biolabs Inc, Subsidiaries 20

★海外企業調査レポート[New England Biolabs Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Stanwell Corporation Ltd:発電所・企業SWOT分析
    Stanwell Corporation Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • MSM Malaysia Holdings Berhad (MSM):企業の財務・戦略的SWOT分析
    MSM Malaysia Holdings Berhad (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Sojitz Corp (2768):企業の財務・戦略的SWOT分析
    Sojitz Corp (2768) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bristol-Myers Squibb Co (BMY):医療機器:M&Aディール及び事業提携情報
    Summary Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and virolo …
  • i-Optics BV-医療機器分野:企業M&A・提携分析
    Summary i-Optics BV (i-Optics) is a medical device company that manufactures and distributes optical devices. The company provides easyscan, eyeprevent and cassini for age related eye diseases. The company’s cassini is a corneal topography measurement device for contact lens fitting, corneal transpl …
  • Brunswick Corporation (BC):企業の財務・戦略的SWOT分析
    Brunswick Corporation (BC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Welltec AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Welltec AS (Welltec) is an oil and gas service provider that develops and offers well technologies and solutions for the oil and gas industries. The company's solutions include wireline services, milling solutions, robotic well solutions, conveyance solutions, clean-out solutions, and mechan …
  • TVS Motor Co Ltd:戦略・SWOT・企業財務分析
    TVS Motor Co Ltd - Strategy, SWOT and Corporate Finance Report Summary TVS Motor Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Symbiomix Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Symbiomix Therapeutics LLC (Symbiomix) is a drug development company that offers development and commercialization of novel medicines. The company offers SYM-1219, for the treatment of several serious infections in women including bacterial vaginosis. Its SYM-1219 contains secnidazole, nitro …
  • EnGeneIC Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary EnGeneIC Ltd (EnGeneIC) is a biopharmaceutical company that develops drugs and other therapeutic molecules. The company develops nanocell platform used as a platform for the creation of custom therapies for cancer. Its cyto-immunotherapy platform releases concentrations of RNA-interference m …
  • Valeant Pharmaceuticals International, Inc.:企業の戦略・SWOT・財務情報
    Valeant Pharmaceuticals International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Valeant Pharmaceuticals International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • American Gene Technologies International Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary American Gene Technologies International Inc (AGT) is a drug development company that tests and commercializes gene-based drugs. The company develops therapies for the treatment of cancer, neurological disorders, AIDS, infectious diseases, Parkinson’s diseases, diabetes, familial dysautonomi …
  • Mannatech Inc (MTEX):企業の財務・戦略的SWOT分析
    Mannatech Inc (MTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lietuvos Draudimas AB:企業の戦略的SWOT分析
    Lietuvos Draudimas AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Sierra Oncology Inc (SRRA):医療機器:M&Aディール及び事業提携情報
    Summary Sierra Oncology Inc (Sierra Oncology), formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company’s product candidate includes SRA737, an orally bioavailable small mo …
  • Ansvar Insurance Limited
    Ansvar Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary Ansvar Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Verastem Inc (VSTM):製薬・医療:M&Aディール及び事業提携情報
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • Etiqa General Insurance Berhad:企業の戦略的SWOT分析
    Etiqa General Insurance Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Long Run Exploration Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Long Run Exploration Ltd (Long Run), formerly WestFire Energy Ltd, a subsidiary of Calgary Sinoenergy Investment Corp, is an oil and gas company that offers development and exploration of light oil. The company grows crude oil volumes within its diversified portfolio properties. Its oil expl …
  • Shanghai Kehua Bio-engineering Co Ltd (002022):企業の財務・戦略的SWOT分析
    Shanghai Kehua Bio-engineering Co Ltd (002022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆